HOME >> BIOLOGY >> NEWS
A friendly foe -- Bacteria residing in the gut boost immune response to tumors

One potent, immune-based treatment for cancer is total body irradiation (TBI). This approach first depletes the body of the population of immune cells known as lymphocytes and then involves the adoptive transfer of tumor-specific T cells to the patient. Lymphodepletion has previously been shown to improve the ability of tumor-specific T cells to cause tumor regression. In a study appearing online on July 26 in advance of publication in the August print issue of the Journal of Clinical Investigation, Nicholas Restifo and colleagues from the National Cancer Institute show that, in mice, lymphodepletion does not fully account for the tumor regression observed following TBI. They show that a disruption of the population of bacteria that normally reside in the gut without causing disease also plays a role in the effectiveness of this therapeutic approach for cancer.

A specific population of bacteria present in our gut is crucial to our health. However, some treatments for cancer, particularly those that deplete the bodys immune cells, have high potential to disrupt the natural balance between our bodies and these commensal microorganisms, causing disease. Restifo and colleagues subjected mice genetically deficient in lymphocytes to TBI and found that, like TBI-treated mice with intact lymphocytes, TBI was still able to positively augment the function of adoptively transferred tumor-specific CD8+ T cells and cause tumor regression. This surprising result indicated that another mechanism for the efficacy of TBI also exists. They found that in these mutant, irradiated mice the lining of their gut was injured, allowing the passage of commensal bacteria from the gut to the lymph nodes, where the immune response to their presence increased the activation of tumor-specific CD8+ T cells and resulted in tumor regression. This effect was found to involve toll-like receptor 4. Conversely, a reduction in the number of host microorganisms by the use of antibiotics reduce
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
26-Jul-2007


Page: 1 2

Related biology news :

1. FSU pushing boundaries with environmentally friendly community
2. New Queens study offers environmentally friendly solution to oil industry needs
3. Eco-friendly bug sucker
4. Research shows Europeans prefer environmentally-friendly seafood
5. Switchable solvents make chemical manufacturing more environmentally-friendly
6. Chemical Society announces EPA awards for environmentally friendly technologies
7. Plant pathologists evaluate eco-friendly alternatives to methyl bromide
8. Fungus-friendly scientists meet in Tucson
9. Bacteria may not hasten death
10. Bacteria ferry nanoparticles into cells for early diagnosis, treatment
11. Bacteria show promise in fending off global amphibian killer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2019)... ... 28, 2019 , ... In the development of biosimilars, the broad definition of ... task. Despite this uncertainty, several manufacturers have been successful and numerous follow-on biologics are ... this webinar, learn how analytical similarity is achieved in biosimilars based on recently approved ...
(Date:3/29/2019)... ... March 29, 2019 , ... ... partnership to expand their broad tissue-based biomarker development capabilities, as well as ... terms of the agreement, the companies will offer a comprehensive set of ...
(Date:3/29/2019)... ... March 29, 2019 , ... GenCure has selected G-CON ... therapy facility. The new facility, which will anchor the VelocityTX innovation center in ... art manufacturing capabilities to support clinical cell therapy trials. GenCure is a subsidiary ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Cirrascale Cloud Services ... has extended its managed services offering to include NVIDIA® DGX™ systems. The company ... of the NVIDIA DGX-Ready Data Center program to deliver a Zero DevOps offering ...
(Date:3/19/2019)... BASEL, Switzerland (PRWEB) , ... ... ... Center at Tel HaShomer, the largest hospital in Israel and the Middle ... cell-therapy manufacturing using the state-of-the-art Cocoon™ manufacturing platform. The partnership will enable ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma ... Center as the fifth institution in Oklahoma to receive this prestigious endorsement. ...
(Date:3/14/2019)... ... March 13, 2019 , ... Murrieta Genomics , the ... bring industry specific and broader business experience to bear as genomic sequencing startups build ... to the knowledge and expertise that our Advisory Board brings to the table. Many ...
Breaking Biology Technology:
Cached News: